

Trial Name	Cancer Indication
IMmotion151	Untreated Advanced Renal Cell Carcinoma
IMpower110	Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
IMpower130	Stage IV Non-Squamous Non-Small Cell Lung Cancer
IMpower131	Stage IV Squamous Non-Small Cell Lung Cancer
IMpower132	Stage IV Non-Squamous Non-Small Cell Lung Cancer
IMpower133	Untreated Extensive-Stage (ES) Small Cell Lung Cancer
IMpower150	Stage IV Non-Squamous Non-Small Cell Lung Cancer
IMpassion130	Untreated Metastatic Triple-Negative Breast Cancer
IMvigor130	Untreated Locally Advanced or Metastatic Urothelial Carcinoma
IMvigor211	Locally Advanced or Metastatic Urothelial Bladder Cancer

Trial/Arm	N (EUR)	Trial/Arm	N (EUR)
IMmotion151/AB	203	IMmotion151/SUN	189
IMpower110/Atezo	97	IMpower110/Chemo	79
IMpower130/ACNabP	200	IMpower130/CNabP	103
IMpower131/ACNabP	155	IMpower131/CNabP	155
IMpower131/ACP	158	IMpower130/CPem	107
IMpower132/ACPem	122	IMpower133/CE	71
IMpower133/ACE	76	IMpower150/BCP	178
IMpower150/ABCP	200	IMpassion130/NabP	132
IMpower150/ACP	223	IMvigor130/PGC	175
IMpassion130/ANabP	145	IMvigor211/Chemo	204
IMvigor130/AGC	151		
IMvigor130/Atezo	121		
IMvigor211/Atezo	224		

Supplementary Table S1. Number of European individuals with genetic data from the clinical trials utilized for analysis of rs2476601 variant. Treatment combinations are abbreviated as follows: Atezo = atezolizumab monotherapy; A = atezolizumab in combination; B = bevacizumab; C = carboplatin; NabP = nab-paclitaxel; P = paclitaxel; Pem= pemetrexed; E = etoposide; G = gemcitabine; SUN = sunitinib; PGC= placebo + GC; Chemo = chemotherapy. NCT numbers are as follows: IMmotion151 (NCT02420821); IMpower110 (NCT02409342); IMpower130 (NCT02367781); IMpower131 (NCT02367794); IMpower132 (NCT02657434); IMpower133 (NCT02763579); IMpower150 (NCT02366143); IMpassion130 (NCT02425891); IMvigor130 (NCT02807636); IMvigor211 (NCT02302807)